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Background: Brain natriuretic peptide (BNP) acts primarily as a cardiac hormone; it is produced by the ventricle 
and has both vasodilatory and natriuretic actions. Therefore, the BNP gene is thought to be a candidate gene for 
essential hypertension (EH). The present study identified variants in the 5’-flanking region of natriuretic peptide 
precursor B (NPPB) gene and assessed the relationship between gene variants and EH.   
Methods: The polymerase chain reaction-single strand conformation polymorphism method and nucleotide se-
quencing were used to identify variants.   
Results: A novel variable number of tandem repeat (VNTR) polymorphism in the 5’-flanking region (-1241 nu-
cleotides from the major transcriptional initiation site) was discovered. This VNTR polymorphism is a tandem 
repeat of the 4-nucleotide sequence TTTC. There were 8 alleles, ranging from 9-repeat to 19-repeat. An associa-
tion study was done involving 317 EH patients and 262 age-matched normotensive (NT) subjects. The 11-repeat 
allele was the most frequent (88.2%); the 16-repeat allele was the second most frequent (10.5%) in the NT group. 
The observed and expected genotypes were in agreement with the predicted Hardy-Weinberg equilibrium val-
ues (P=0.972). Among females, the overall distribution of genotypes was significantly different between the EH 
and NT groups (p=0.039). The frequency of the 16-repeat allele was significantly lower in the female EH group 
(6.5%) than in the female NT group (12.2%, p=0.046). 
Conclusions: The 16-repeat allele of the VNTR in the 5’-flanking region of NPPB appears to be a useful genetic 
marker of EH in females. 
Key words: Brain natriuretic peptide, essential hypertension, variable number of tandem repeat, association study 
1.  Introduction 
Natriuretic peptides constitute a family of three 
structurally related molecules: atrial natriuretic pep-
tide (ANP) [1], brain natriuretic peptide (BNP) [2], and 
C-type natriuretic peptide (CNP) [3]. ANP and BNP 
act mainly as cardiac hormones and are produced 
primarily by the atria and ventricles, respectively, 
whereas C-type natriuretic peptide is expressed 
mainly in the brain [4,5]. 
BNP, which was originally isolated from the por-
cine brain [6], shows an amino acid sequence homol-
ogy to ANP. BNP has central and peripheral actions 
that are similar to those of ANP. The heart has the 
highest concentrations of BNP, and BNP acts as a car-
diac hormone. Intravenous injection of BNP causes a 
significant decrease in blood pressure [7]. Transgenic 
mice that overexpress BNP have a measurable reduc-
tion in blood pressure [8]. Mukoyama et al. showed 
that plasma BNP levels are higher in individuals with 
essential hypertension (EH) than in normotensive (NT) 
individuals [7]. These findings suggest that the BNP 
gene is a candidate gene for EH. EH is thought to be a 
multifactorial disorder; several studies have shown 
that an association analysis with genetic variants can 
be used to identify susceptibility genes for EH [9]. 
The aim of the present study was to identify mu-
tations or polymorphisms in the 5’-flanking region of 
the NPPB gene and to assess the relationship between 
variants of the gene and EH. 
2.  Subjects and Methods  
Subjects  
The EH group consisted of 317 patients (mean 
age, 49.7 ± 7.8 years) with EH diagnosed based on sit-
ting systolic blood pressure (SBP) greater than 160 Int. J. Med. Sci. 2007, 4 
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mmHg and/or diastolic blood pressure (DBP) greater 
than 100 mmHg measured on three separate occasions 
within 2 months after the initial BP measurement (Ta-
ble 1). These patients were not being treated with an-
tihypertensive drugs. All EH subjects had a positive 
family history of hypertension; patients diagnosed 
with secondary hypertension were excluded from the 
study. We also enrolled 262 healthy, normotensive 
(NT) subjects (mean age, 51.2 ± 10.8 years). None of 
the NT subjects had a family history of hypertension; 
all had an SBP less than 130 mmHg and a DBP less 
than 85 mmHg. A family history of hypertension was 
defined as having grandparents, uncles, aunts, parents, 
or siblings who had been diagnosed with hyperten-
sion. Written informed consent was obtained from 
each subject based on a protocol approved by the Eth-
ics Committee of the Nihon University School of 
Medicine and the Clinical Studies Committee of Ni-
hon University Hospital [10]. 
Table 1. Characteristics of study participants 
 
Biochemical analysis 
Plasma total cholesterol concentrations, as well as 
serum creatinine and uric acid concentrations, were 
measured using standard methods in the Clinical 
Laboratory Department of Nihon University Hospital 
[11]. Plasma BNP levels were measured in NT subjects 
and EH patients. A total of 76 subjects (43 in the NT 
group and 33 in the EH group) who did or did not 
have the 16 repeat allele were selected randomly. 
Plasma BNP levels were measured using a highly sen-
sitive immunoradiometric assay (Shiono RIA BNP 
assay kit, Shionogi Co., Ltd., Tokyo, Japan) as de-
scribed previously [12]. 
Polymerase chain reaction - single strand confor-
mation polymorphism (PCR-SSCP) 
Genomic DNA was extracted from peripheral 
blood leukocytes using a standard method [13]. To 
screen for mutations, two oligonucleotide primers 
(sense, 5’- AAGGAGGCACTGGGAGAGGGGAAAT 
-3’ (bases -1323 to -1299 from the major transcriptional 
initiation site) and antisense, 
5’-AATTAGCTGGGCATGGTGGCAGGCG-3’ (bases 
-1075 to -1051)) that recognize part of the 5’-flanking 
region of the NPPB gene were designed, since this re-
gion has been reported to be a major promoter region 
(Fig. 1A) [14]. PCR-SSCP was done (GenePhor System; 
Amersham Biosciences Corp, Piscataway, NJ, USA) 
[15]. PCR was performed using a GeneAmp PCR sys-
tem 9700 (Applied Biosystems, Branchburg, NJ, USA) 
with the following amplification conditions: initial 
denaturation at 96°C for 3 min followed by 35 cycles of 
98.5°C for 25 s, 65°C for 30 s, 68°C for 30 s, and a final 
extension of 68°C for 10 min. PCR products were 
separated by electrophoresis on 10% precast poly-
acrylamide gels (Amersham Biosciences Corp) at 5°C 
for 80 min and then subjected to silver staining 
(Dai-ichi Kagaku, Tokyo, Japan). The electrophoresis 
parameters were set according to the manufacturer’s 
protocol. 
Sequencing analysis 
Two oligonucleotides (sense, 
5’-AAGGAGGCACTGGGAGAGGGGAAAT-3’ (bases 
-1323 to -1299) and antisense, 5’- 
CCCCACCAAGCCAACACAGGATGGA -3’ (bases 
-919 to-895) were used to amplify a 429-bp product 
from genomic DNA (Fig. 1A). The PCR products were 
purified using a Microcon 100 column (U.S. Amicon 
Inc. Beverly, MA,USA). The resulting products were 
ligated to pCR2.1TM vectors and cloned (TA Cloning 
Kit, Invitrogen, San Diego, CA, USA). The ligation of 
the products was confirmed by direct DNA sequenc-
ing (ABI PRISM 310 Genetic Analyzer) [16].  
Genotyping 
Genotyping was done using fragment analysis, 
and the sequencing primers were used. PCR amplifi-
cation consisted of an initial denaturation at 94°C for 3 
min, followed by 35 cycles of 98.5°C for 25 sec, 63°C for 
30 s, 72°C for 1 min, and a final extension of 72°C for 10 
min. Then, the PCR products were analyzed using an 
automatic electrophoresis system (Agilent 2100 bio-
analyzer systemTM; Agilent Technologies, Waldbronn, 




Data are presented as the mean ± SD. The 
Hardy-Weinberg equilibrium was assessed by doing 
chi-square (χ2) analysis. Differences in the clinical data 
between the EH and NT groups were assessed by 
analysis of variance (ANOVA). The distributions of 
the genotypes or alleles between EH patients and NT 
subjects were tested using a two-sided Fisher’s exact 
test. Multiple logistic regression analyses were done to 
assess the contribution of confounders (gender, BMI) 
[17]. A value of P < 0.05 was considered statistically 
significant.  
 
Figure 1 A: Nucleotide sequence of the 5’-flanking region of the human NPPB gene. The nucleotide sequences are numbered (left) 
with respect to the major transcription start site (designated +1; closed triangle). Boxes, the primers (PCR-SSCP); double under-
lining, the primers (sequence and genotyping); overlining, ATG initiation codon; Underlining, the variable number of tandem repeat 
(VNTR) consists of the 4 nucleotides (TTTC). This figure shows the 11 repeat types. B: Nucleotide sequence of the 11 and 16 repeat 
allele. 
 
3.  Results 
We discovered a novel variable number of tan-
dem repeat (VNTR) polymorphism consisting of a 
11-nucleotide repeat of 4 base pairs (bp) in the 
5’-flanking region (-1241 nucleotides from the major 
transcriptional initiation site) (GenBank accession 
number AB265677). This VNTR polymorphism is a 
tandem repeat of the 4-nucleotide sequence TTTC (Fig. 
1A). There were 8 alleles of this VNTR polymorphism, 
ranging from 9-repeat to 19-repeat (Fig. 1B). 
The association study showed that the 11-repeat 
allele was most frequent in the NT group (88.2%). The 
16-repeat allele was second most frequent in the NT 
group (10.5%). Furthermore, in the NT group, the ob-
served and expected genotypes were in good agree-
ment with the predicted Hardy-Weinberg equilibrium 
values (P=0.972). Of note, the overall distribution of 
genotypes in females was significantly different be-
tween the EH and NT groups (p=0.039); the frequency 
of the 16-repeat allele was significantly lower in the 
EH group (6.5%) than in the NT group (12.2%, p=0.046) 
(Table 2). 
On multiple logistic regression analysis, a sig-
nificant association between allele 16 (p=0.034) and 
female gender was noted, even after adjustment for 
confounding factors; the calculated odds ratio was 
1.18 (95%CI: 1.07-1.20). 
The clinical data of each genotype were assessed. 
There were no significant differences in SBP and DBP 
levels, or in the pulse of subjects with or without the 
16 repeat allele (Table 3). 
The plasma BNP level was significantly higher in 
the EH group than in the NT group (p=0.0203). The 
plasma BNP level in each genotype with or without 
the 16 repeat allele was determined (Table 4); there 
were no significant differences among the groups. It 
was impossible to perform this analysis in EH females, 
as none of them had the 16 repeat allele. 
All subjects were classified into 3 groups based 
on their BMI levels (lean, BMI<18.5; normal, 
18.5<BMI<25; obese, BMI >25). There was no associa-Int. J. Med. Sci. 2007, 4 
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tion between the genotype and the BMI among the  groups  (Table  5).  
Table 2. Genotype distribution in NT subjects and EH patients 
 
Table 3. The association between genotype and phenotype 
 
Table 4. Plasma BNP levels for patients with or without 16 repeat 
 
Table 5. Distribution of subjects by BMI 
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4.  Discussion  
Ogawa et al. reported that the 5’-flanking region 
of the 1.9 kilo-base pairs in the NPPB gene has a high 
transcriptional activity. Using the deletion mutant 
model, the deletion of sequences between -1288 and 
-1095 reduced transcriptional activity to approxi-
mately 30%. These deleted sequences contain a char-
acteristic CT-rich region (-1248 to -1191), followed by 
an Alu family sequence (-1190 to -934). Thus, these 
results are consistent with the hypothesis that Alu re-
peat sequences in the 5’-flanking regions have regula-
tory roles in NPPB expression [14]. Therefore, we as-
sessed the association between mutations or poly-
morphisms in the 5’-flanking region of NPPB and the 
presence of EH. In the present study, a novel VNTR 
was discovered, and a significant association between 
the VNTR and EH was found in female patients. The 
present study found that the number of patients with a 16 
repeat allele of VNTR was lower in EH women than in NT 
women. It is well known that the plasma BNP level is 
higher in EH patients than in NT subjects, since an 
elevated blood pressure results in a high plasma BNP 
level, which is one of the protective factors for hyper-
tension [4]. We compared the plasma BNP levels of pa-
tients with and without the 16 repeat allele and found that 
there was no significant difference between the two groups. 
In fact, there were not enough subjects to allow the 
association studies to be done by gender. Given our 
results, these limitations should be addressed in future stud-
ies. It is possible that factors other than the NPPB gene 
may have affected the BNP levels, since many factors, 
including cardiac function and blood pressure, are 
known to affect human plasma BNP levels. Thus, it is 
possible that the plasma BNP level is not an accurate 
reflection of the function of the NPPB gene. 
In the present study, the overall distribution of 
the VNTR genotype and the allele frequency were 
significantly different in females but not in males. 
Gender-specific susceptibility to EH is an interesting 
finding, but its importance is still unclear [11]. Red-
field et al. reported that BNP levels increased with age, 
and were higher in females than males among subjects 
with no known cardiovascular or detectable structural 
heart disease [18]. Maffei et al. reported that hormone 
replacement therapy increased BNP levels in post-
menopausal women [19]. Although the absolute BNP 
value was different between these two studies, which 
used two different assays, the associations of the BNP 
levels with age and gender were consistent. Further-
more, the BNP level that had the optimal sensitivity 
and specificity for detecting systolic dysfunction in the 
overall population increased with age and was higher 
in women. This underscores the clinical relevance of 
the relationship of age, gender, and BNP. In both 
studies that used different assays, the effect of gender 
on BNP was substantial and independent of other 
factors [18]. Unfortunately, we were not able to obtain 
samples to measure plasma BNP and ANP levels, due 
to the difficulty in obtaining written informed consent 
for blood examinations from subjects not receiving 
medications. 
In the Japanese population, it has been reported 
that plasma BNP levels are positively associated with 
age, urinary salt excretion, higher blood pressure, a 
high R-wave voltage in the 12-lead ECG (Code 3-1 or 
3-3), and female gender [20,21]. On the other hand, 
Freitag et al., based on multivariate models adjusting 
for known risk factors, showed that elevated plasma 
BNP levels were associated with an increased risk of 
blood pressure progression in males but not in fe-
males. However, there was no significant trend of an 
increasing incidence of hypertension among BNP 
categories in either males or females. In a commu-
nity-based sample, higher plasma BNP levels were 
found to be associated with an increased risk of BP 
progression in males, but not in females [22]. Further 
studies are needed to resolve these conflicting results. 
Since there are many loci with a high degree of 
polymorphism in the number of tandemly repeated 
nucleotide sequence units, VNTR polymorphisms, 
also called minisatellites, were originally studied for 
linkage-mapping purposes. VNTRs have a highly po-
lymorphic nature that makes them very useful as 
markers, both in linkage studies to map disease loci in 
families and in forensic applications. Recent reports 
indicate that some VNTR sequences may function as 
transcriptional or translational regulators, and that 
they may modify the function of a protein when the 
tandemly repeated region lies within the coding re-
gion of the gene [23]. Although no clear effect on 
transcription has been shown, it has been reported 
that a VNTR in the second intron of the serotonin 
transporter gene is associated with susceptibility to 
major depression [24].   
We previously determined the structural organi-
zation of human natriuretic peptide receptor genes 
[25-28] and identified an insertion/deletion mutation 
in the 5’-untranslated region of NPRA [12]. The dele-
tion encompasses eight nucleotides and alters the 
binding sites for the AP2 and zeste transcription fac-
tors. Transcriptional activity of the deletion allele was 
less than 30% that of the wild-type allele. The deletion 
allele was significantly more common in the EH group 
than in the NT group. These findings suggest that in 
Japanese individuals, this deletion in the NPRA gene 
reduces receptor activity and may confer increased 
susceptibility for the individual to develop EH or left 
ventricular hypertrophy (LVH). Animal models with a 
deletion of this gene develop disorders that resemble 
the symptoms of subjects with a deleted allele in the 
5’-untranslated region of NPRA. We previously iso-
lated a missense mutation of the NPRA gene [29] and 
a VNTR polymorphism upstream of the NPRC gene; 
this VNTR influences blood pressure levels in obe-
sity-associated hypertension [30]. Since the sampling 
of the above reports was different from the present 
experiment, it was impossible to analyze the relation-
ship between systemic natriuretic peptide genes and 
EH.  
Wang et al. reported that obese individuals have 
low circulating natriuretic peptide levels, which may 
contribute to their susceptibility to hypertension and Int. J. Med. Sci. 2007, 4 
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hypertension-related disorders. The mechanisms 
linking obesity to hypertension have not been estab-
lished, but sodium retention and excessive sympa-
thetic tone are key contributors. Natriuretic peptides 
are important regulators of sodium homeostasis and 
neurohormonal activation; this raises the possibility 
that obese individuals have an impaired natriuretic 
peptide response [31]. Therefore, we examined the 
relationship between the genotype and BMI and 
found no significant association. 
In conclusion, a novel VNTR in the 5’-flanking 
region of the NPPB gene was discovered. This poly-
morphism was associated with EH in female subjects. 
However, this finding does not necessarily imply that 
there is a relationship between the NPPB gene and EH. 
Further studies of other polymorphisms are needed to 
determine whether there is an association between the 
NPPB gene and EH.   
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